Medical update and roster consequences
Jalen Hurts will miss the remainder of the 2026 season after testing showed blood clots had moved into his lungs, ending his campaign.
The diagnosis and subsequent treatment have immediate roster and preparation implications for the Eagles, but they also opened broader questions about how the club handled the quarterback’s care in the days leading up to the injury’s discovery.
Timeline and the scrutiny over decisions
Hurts complained of calf pain on Oct. 8, and the Eagles reportedly discovered a superficial blood clot on Oct. 10 — hours before the team’s Oct. 11 game against the Jacksonville Jaguars in London. The fact that Hurts played in that Week 5 matchup after the clot was identified has become the focal point of public scrutiny and internal questioning.
League medical leadership defended the club’s handling. NFL chief medical officer Allen Sills defended the Eagles’ medical staff and said it was "nonsense" to suggest football would impact a medical decision, and Jeff Miller, the league executive overseeing health and safety, reiterated that view.
That official defense contrasts with outside commentary alleging a delay in starting blood-thinner treatment. The Athletic’s Michael Silver pointed out that the team’s decision to allow Hurts to fly to London delayed initiating anticoagulant therapy, a detail that has intensified criticism of the timing and prudence of the Eagles’ choices.
Questions, pushback and calls for answers
The situation has prompted debate about whether the Eagles’ injury reporting and internal decision-making met medical and league standards. ESPN’s NFL insider Adam Schefter has challenged claims that the Philadelphia Eagles mishandled Jalen Hurts’ medical situation, saying more information is needed before apportioning blame; Schefter also questioned what punishment, if any, the Eagles could face and noted the club listed Hurts’ problem on the injury report as a calf issue.
At the same time, observers and critics have asked whether that listing accurately reflected Hurts’ underlying diagnosis. If investigators determine the club misrepresented the condition on injury reports, that could lead to consequences, a point Schefter also underscored when separating medical concerns from potential rule violations.
For now, the confirmed medical facts are clear: Hurts is out for the season, is on blood thinners, and will not play until cleared off that therapy. The procedural questions — why the initial clot wasn’t treated with anticoagulants before the London trip, whether reporting captured the true nature of the injury, and what, if any, league response will follow — remain unresolved and are driving the scrutiny around the Eagles’ decision-making.
